2024 年 3 月,J Extracell Vesicles 发表一项临床研究 PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer,发现即使患者...
2024 年 3 月,J Extracell Vesicles 发表一项临床研究 PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer,发现即使患者组织中 PD-L1 表达水平较低,只要胞外囊泡(EVs)中 PD-L1 表达水平高也...
(PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer. J Extracell Vesicles. 2024 May;13(5):e12443. IF=15.5 1区) 小结 前面所述的研究,在非小细胞肺癌和转移性黑色素瘤中,证实了胞外...
在围手术期领域,CheckMate 816和KEYNOTE-671研究中,PD-L1<1%患者接受新辅助免疫联合化疗,对比单纯化疗尽管未能改善EFS,但可以显著改善MPR和pCR[5,7],结果提示了新辅助免疫联合化疗用于PD-L1表达阴性患者的潜力。本研究评估了,不同PD-L1...
用游戏语言来说的话,双抗已经渐渐有“版本答案”那味儿了,尤其是在PD-L1阴性/低表达人群。 2024年4月8日凌晨,第115届美国癌症研究协会(AACR)召开的第三天,议程终于行进到了Clinical trial环节。 8项精选的临床试验在当天的临床试验全体大会上进行了口头报告,其中一项来自中国,是康方生物的PD-1/CTLA-4双抗卡度...
PD-L1Immunotherapy has revolutionized the treatment of patients with non-small cell lung cancer (NSCLC). High expression of tissue PD-L1 (tPD-L1) is currently the only approved biomarker for predicting treatment response. However, even tPD-L1 low (1-49%) and absent (<1%) pa...
In result, PD-L1 positive patients had a shorter PFS compared to PD-L1 negative patients (median 7.1 months vs. median not reached: P = 0.017) (Fig. 5B). Notably, one of the patients who had a high PD-L1 (+) CTC counts at visit 2 and visit 3 was put on therapy with PD-...
2021年12月发表于 cell子刊Cancer Cell(IF=31.743)上的“Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer”; PD-1/PD-L1研究联合单细胞测序在三阴性乳腺癌(TNBC)中,联合化疗和检查点抑制剂的作用机制尚未明确。在本篇文章中,研...
The median postoperative survival of exosomal PD-L1-negative patients was significantly longer (17.2 months) than exosomal PD-L1- positive patients (7.8 months) (P = 0:043). [105] Levels of exosomal PD-L1 levels of stage I- II (15:90 ± 6:45 pg/mL) and III/IV...
所以研究认为PD-L1阴性的晚期非小细胞肺癌患者,依旧可以从化疗+免疫治疗中获益 两项Mete分析都告诉我们,驱动基因阴性,PD-L1阴性的晚期非小细胞肺癌患者,一线治疗,化疗+免疫治疗优于单纯化疗,可以提高ORR、PFS、OS 但问题来了,目前驱动基因阴性患者...